Skip to main content
. 2007 Jan 10;91(6):743–745. doi: 10.1136/bjo.2006.107466

Table 1 Best‐corrected visual acuity and foveal thickness in patients treated with topical 2% dorzolamide.

Patient no Visit number, months of follow‐up Vision FT, mean FT difference (%) FZT,* mean FZT difference (%)
OD OS OD OS OD OS
1 1 20/50 (−2) 20/30 (−2) 356 491 343 456
2, 1 20/40 (+2) 20/25 (−1) 158 (−56) 419 (−15) 219 (−36) 395 (−13)
3, 2 20/25 (−2) 20/25 (−1) 144 (−60) 464 (−5) 208 (−39) 428 (−6)
4, 4 20/30 (+2) 20/25 (−2) 158 (−56) 482 (−2) 225 (−34) 435 (−5)
5, 10 20/30 (−1) 20/25 (−1) 255 (−28) 423 (−14) 284 (−17) 404 (−11)
2 1 20/40 (+2) 20/40 (−3) 515 496 514 495
2, 2 20/40 (−1) 20/40 (−3) 396 (−23) 482 (−3) 412 (−20) 458 (−7)
3, 3 20/40 (−2) 20/40 (−2) 404 (−22) 441 (−11) 413 (−20) 445 (−10)
4, 5 20/40 20/40 (−2) 378 (−27) 395 (−20) 386 (−25) 402 (−19)
5, 7 20/30 (−2) 20/40 (−2) 423 (−18) 444 (−10) 425 (−17) 440 (−11)
6, 9 20/30 20/40 (−1) 364 (−29) 372 (−25) 375 (−27) 376 (−24)
7, 12 20/40 (+2) 20/40 (+2) 461 (−10) 502 (+1) 463 (−10) 493 (−1)
3 1 20/40 (−2) 20/50 (+1) 574 523 530 489
2, 2 20/30 20/30 (+1) 174 (−70) 201 (−62) 235 (−56) 254 (−48)
3, 3 20/30 20/30 (+2) 179 (−69) 177 (−66) 239 (−55) 230 (−53)
4, 4 20/30 20/30 (+1) 200 (−65) 198 (−62) 269 (−49) 245 (−50)
5, 10 20/30 (+2) 20/30 (+2) 163 (−72) 179 (−66) 227 (−57) 230 (−53)
6, 15 20/30 20/30 (+2) 234 (−59) 221 (−58) 288 (−46) 260 (−47)
4 1 20/50 (−3) 20/60 (−1) 315 338 321 333
2, 1 20/40 (−1) 20/60 (+1) 250 (−21) 280 (−17) 264 (−18) 284 (−15)
3, 3 20/40 (−2) 20/60 226 (−28) 238 (−30) 242 (−25) 251 (−25)
4, 8 20/40 20/60 213 (−32) 242 (−28) 239 (−25) 261 (−22)
5, 13 20/40 (+2) 20/50 (−1) 213 (−32) 281 (−17) 243 (−24) 295 (−11)
5 1 20/30 (+1) 20/40 (+2) 340 311 349 323
2,1 20/25 20/30 (+2) 263 (−23) 249 (−20) 288 (−17) 280 (−13)
3, 2 20/25 20/25 (−2) 309 (−9) 285 (−8) 318 (−9) 302 (−6)
4, 3 20/25 (+1) 20/25 (+1) 298 (−12) 250 (−20) 309 (−11) 279 (−14)
5, 4 20/25 (−3) 20/30 (+2) 220 (−35) 219 (−30) 261 (−25) 250 (−23)
6, 9 20/25 (−3) 20/30 (−1) 222 (−35) 250 (−20) 267 (−23) 278 (−14)
7, 12 20/25 (−2) 20/30 (−1) 213 (−37) 233 (−25) 258 (−26) 263 (−19)
6 1 20/20 (−2) 20/25 (−2) 273 643 303 607
2, 2 20/20 20/25 (−1) 239 (−12) 523 (−19) 273 (−10) 516 (−15)
3, 3 20/20 20/25 (−2) 228 (−16) 413 (−36) 262 (−14) 427 (−30)
4, 5 20/20 20/20 (−1) 237 (−13) 512 (−20) 272 (−10) 506 (−17)
5, 7 20/20 20/20 (−3) 241 (−12) 584 (−9) 280 (−8) 567 (−7)
7 1 20/30 (−3) 20/30 (−1) 310 225 307 256
2, 1 20/30 (+2) 20/25 (+2) 228 (−26) 162 (−28) 251 (−18) 217 (−15)
3, 3 20/25 (−2) 20/25 (−2) 169 (−45) 150 (−33) 215 (−30) 207 (−19)
4, 5 20/25 (−1) 20/25 (−2) 217 (−30) 271 (+20) 159 (−48) 223 (−13)
5, 7 20/25 (−1) 20/25 (−2) 160 (−48) 155 (−31) 208 (−32) 214 (−16)
6, 10 20/25 (−2) 20/25 (−1) 166 (−46) 145 (−36) 224 (−27) 219 (−14)
7, 13 20/25 (−2) 20/25 (−2) 234 (−25) 155 (−31) 266 (−13) 216 (−16)
8 1 20/60 (+2) 20/30 (+1) 261 326 256 334
2, 1 20/50 (−3) 20/30 (+2) 217 (−17) 230 (−34) 224 (−13) 253 (−24)
3, 3 20/50 (−2) 20/25 (−2) NA 208 (−36) NA 246 (−26)
4, 6 20/60 (−2) 20/25 (−2) 214 (−18) 208 (−36) 237 (+7) 235 (−30)
5, 9 20/70 (+1) 20/30 (−1) 259 (−1) 286 (−12) 260 (+1) 307 (−8)
6, 11 20/50 (−2) 20/25 (−2) 235 (−10) 260 (−26) 270 (+5) 281 (−16)

FT, foveal thickness; FZT, foveal zone thickness; OD, oculus dexter; OS, oculus sinister.

*FZT (defined as the central 1000 µ centred on the fovea).

†Bold numbers represent a significant difference of FT and FZT between visits for each patient. Determination of significant difference was based on intervisit variation (upper range and mean (2SD)) of FT and FZT changes in a control group (n = 5) with retinitis pigmentosa patients with continuing medical education (CME) (FT>16%, FZT>11%).

Positive and negative values for differences represent a direction of change: a “+” value indicates an increase in the FT or FZT, whereas a “−” value indicates a decrease in the FT or FZT. NA indicates that data could not be obtained.